GlassScriptPhysician profile
Thomas W Montgomery
NPI 1093796690
$4,729.90
in general payments reported to CMS, 2019-2025
32 companies · $936 in 2025
The $936 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $491 · 2021: $348 · 2022: $667 · 2023: $690 · 2024: $1,012 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $823.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $527.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $420.46 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $397.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $281.22 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $247.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $228.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $194.03 | 2020-2024 | Eliquis |
| Amgen INC. | $193.90 | 2019-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $186.53 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $159.73 | 2019-2025 | Gardasil 9, Capvaxive |
| Lilly USA, LLC | $146.10 | 2021-2025 | Jardiance, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.09 | 2019-2025 | Ofev, Tradjenta, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.00 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $118.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $109.15 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.72 | 2024-2025 | |
| Dexcom, INC. | $53.42 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $49.33 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $35.59 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.68 | 2025 | Caplyta |
| Genzyme Corporation | $28.42 | 2022 | |
| Endogastric Solutions, INC | $24.83 | 2022 | |
| Boston Scientific Corporation | $24.43 | 2025 | General - Pain Management |
| Eisai INC. | $21.43 | 2025 | |
| Shield Therapeutics INC | $19.93 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.82 | 2025 | Rexulti |
| Lundbeck LLC | $18.02 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $14.41 | 2024 | Voquezna |
| Allergan, INC. | $14.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.